Skip to main content
. 2014 Jul 21;111(31):11365–11370. doi: 10.1073/pnas.1411701111

Fig. 4.

Fig. 4.

JQ1 synergize with ibrutinib in killing ABC DLBCLs. (A) Combination responses for the BET inhibitor JQ1 and the IKKβ inhibitor SPC-839 as judged by a 10 × 10 viability matrix. TMD8 cells viability was measured at 48 h posttreatment by CellTiterGlo assay (Left). An isobologram analysis of viability data are shown on the Right. (B) Same as in A, but the combination between JQ1 and the BTK inhibitor ibrutinib was analyzed. (C) The indicated cell lines were treated with a large concentration range of BTK inhibitor ibrutinib, in combination with either DMSO or three different concentration of JQ1. Shown is the relative viability of each combination subset, as assessed by MTS assay at day 4 posttreatment. (D) Relative IκBα-luciferase activity in the ABC DLBCL TMD8 cell line. Cells were treated overnight (16 h) with indicated concentration of ibrutinib, in combination with either DMSO or three different concentration of JQ1. Error bars represent SEM of triplicates.